“Whether a generic drug manufacturer ‘has committed acts of infringement’ under 28 U.S.C. § 1400(b) in a judicial district by submitting an Abbreviated New Drug Application (‘ANDA’) seeking approval to market an infringing generic drug throughout the United States, including in that judicial district.”
